APT Therapeutics™ is developing optimized human apyrases as safe, effective, and cost-competitive antiplatelet therapy for acute myocardial infarction, stroke and transplantation complications. The business strategy is to out-license or co-develop the drug candidates with pharma partners. The Company was incorporated in 2001 and is headquartered in St Louis, Missouri.